Skip to main content
Premium Trial:

Request an Annual Quote

Precision BioSciences Files Fourth Patent Lawsuit Against Cellectis

NEW YORK (GenomeWeb News) – Precision BioSciences today said it has filed a fourth lawsuit against Cellectis and a number of its affiliates alleging patent infringement.

The company filed its lawsuit in US District Court for the Eastern District of North Carolina claiming Cellectis infringes on US Patent No. 8,124,369, which relates to Precision Bio's Directed Nuclease Editor genome engineering technology.

The Research Triangle Park, N.C.-based genetic engineering company is asking for monetary damages, a permanent injunction against Cellectis from making, using, selling, offering for sale, or importing infringing engineered meganucleases in the US.

Precision Bio filed two lawsuits against the French firm last week as well as one in the fall.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.